X4 Pharmaceuticals, Inc (XFOR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 15M 30M 45M Q3 '19: 3.5M Q4 '19: 0 Q1 '20: 3M Q2 '20: 3M Q3 '20: 3M Q4 '20: 3M Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 563K Q3 '24: 1.1M Q4 '24: 2.6M Q1 '25: 31.4M Q2 '25: 32.8M Q3 '25: 34M Q4 '25: 35.1M Q1 '26: 9M Q2 '26: 15.8M Q1 '20 Q4 '20 Q3 '21 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 10M 20M 30M Q4 '23: 0 Q1 '24: 0 Q2 '24: 295K Q3 '24: 628K Q4 '24: 1.8M Q1 '25: 25.9M Q2 '25: 27.2M Q3 '25: 28.3M Q4 '25: 29.4M Q1 '26: 7.4M Q2 '26: 12.9M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-120M -80M -40M 0 40M 80M 120M Q4 '17: -22.2M Q1 '18: -22.5M Q2 '18: -23.3M Q3 '18: -18.8M Q4 '18: -29.1M Q1 '19: -33.4M Q2 '19: -40.5M Q3 '19: -48.9M Q4 '19: -51.7M Q1 '20: -51.8M Q2 '20: -53.1M Q3 '20: -53.1M Q4 '20: -59.9M Q1 '21: -67.2M Q2 '21: -71.6M Q3 '21: -73.7M Q4 '21: -85.1M Q1 '22: -88.4M Q2 '22: -90M Q3 '22: -91M Q4 '22: -87.6M Q1 '23: -95.6M Q2 '23: -100.8M Q3 '23: -107.9M Q4 '23: -107.5M Q1 '24: -115.5M Q2 '24: -18.6M Q3 '24: -25.9M Q4 '24: -36.4M Q1 '25: -8.6M Q2 '25: -105.9M Q3 '25: -98.9M Q4 '25: -86.9M Q1 '26: -97.7M Q2 '26: -87.9M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '17: -33.9M Q1 '18: -35.9M Q2 '18: -36.2M Q3 '18: -33.2M Q4 '18: -31.4M Q1 '19: -34.9M Q2 '19: -42.2M Q3 '19: -51.3M Q4 '19: -52.8M Q1 '20: -53.1M Q2 '20: -54.8M Q3 '20: -54.6M Q4 '20: -62.1M Q1 '21: -69.7M Q2 '21: -74.2M Q3 '21: -76.9M Q4 '21: -88.7M Q1 '22: -92M Q2 '22: -93.6M Q3 '22: -95M Q4 '22: -93.9M Q1 '23: -95.9M Q2 '23: -130.4M Q3 '23: -111.1M Q4 '23: -101.2M Q1 '24: -128.9M Q2 '24: 17.6M Q3 '24: -16.8M Q4 '24: -37.5M Q1 '25: 14.6M Q2 '25: -102M Q3 '25: -95.1M Q4 '25: -79.2M Q1 '26: -99.7M Q2 '26: -90.1M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 2M 4M 6M Q4 '23: 0 Q1 '24: 0 Q2 '24: 268K Q3 '24: 495K Q4 '24: 797K Q1 '25: 5.5M Q2 '25: 5.6M Q3 '25: 5.7M Q4 '25: 5.8M Q1 '26: 1.6M Q2 '26: 2.9M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow TTM

-210M -140M -70M 0 70M 140M 210M Q4 '17: -21.3M Q1 '18: -24M Q2 '18: -23.4M Q3 '18: -25M Q4 '18: -25.4M Q1 '19: -31M Q2 '19: -39.5M Q3 '19: -45.5M Q4 '19: -48.1M Q1 '20: -51.8M Q2 '20: -49M Q3 '20: -50.6M Q4 '20: -58.8M Q1 '21: -61.7M Q2 '21: -69.5M Q3 '21: -69.4M Q4 '21: -70.9M Q1 '22: -72.7M Q2 '22: -72M Q3 '22: -77.1M Q4 '22: -77.1M Q1 '23: -83.4M Q2 '23: -112.8M Q3 '23: -162.3M Q4 '23: -171M Q1 '24: -178M Q2 '24: -194M Q3 '24: -159.3M Q4 '24: -164.5M Q1 '25: -143.3M Q2 '25: -109.3M Q3 '25: -103.1M Q4 '25: -85.6M Q1 '26: -92.8M Q2 '26: -83.7M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-210M -140M -70M 0 70M 140M 210M Q4 '17: -21.7M Q4 '19: -48.2M Q1 '20: -52.6M Q2 '20: -49.7M Q3 '20: -51.7M Q4 '20: -60.2M Q1 '21: -63M Q2 '21: -70.9M Q3 '21: -70.3M Q4 '21: -71.5M Q1 '22: -72.8M Q2 '22: -72.1M Q3 '22: -77.1M Q4 '22: -77.2M Q1 '23: -83.5M Q2 '23: -112.9M Q3 '23: -162.4M Q4 '23: -171M Q1 '24: -178.2M Q2 '24: -194.3M Q3 '24: -159.6M Q4 '24: -164.8M Q1 '25: -143.6M Q2 '25: -109.4M Q3 '25: -103.1M Q4 '25: -85.6M Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q3 '21: 26.6M Q1 '22: 33.7M Q2 '22: 35.4M Q3 '22: 83.2M Q1 '23: 146M Q2 '23: 168.7M Q3 '23: 197M Q1 '24: 6.7M Q2 '24: 6.7M Q3 '24: 6.7M Q1 '25: 6.9M Q2 '25: 7.4M Q3 '25: 43.3M Q1 '26: 126.3M Q2 '26: 126.3M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q4 '17: -45.90 Q1 '18: -53.11 Q2 '18: -56.81 Q3 '18: -54.60 Q4 '18: -53.57 Q1 '19: -42.54 Q2 '19: -28.73 Q3 '19: -9.56 Q4 '19: -4.63 Q1 '20: 1.48 Q2 '20: 1.74 Q3 '20: 2.09 Q4 '20: -3.10 Q1 '21: -3.84 Q2 '21: -3.82 Q3 '21: -3.71 Q4 '21: -4.08 Q1 '22: -3.50 Q2 '22: -3.36 Q3 '22: -2.86 Q4 '22: -1.78 Q1 '23: -1.22 Q2 '23: -0.95 Q3 '23: -0.70 Q4 '23: -17.09 Q1 '24: -24.70 Q2 '24: -10.80 Q3 '24: -16.27 Q4 '24: -5.59 Q1 '25: 2.22 Q2 '25: -14.82 Q3 '25: -10.03 Q4 '25: -1.87 Q1 '26: -2.07 Q2 '26: 1.27 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.